When Strength Suddenly Slips Away: Larisa’s Journey to a Myositis Diagnosis

Larisa
Immunology Innovation

When Strength Suddenly Slips Away: Larisa’s Journey to a Myositis Diagnosis

Patient Detail

In 2023, Larisa and her husband were training to walk the Camino de Santiago, a network of historic pilgrimage routes across Spain. Together they were building endurance, setting goals, and planning ahead for their travels, until something began to shift. “I would go to the gym and couldn’t lift the weights I used to. I could barely walk the treadmill,” Larisa recalls. “Then I started falling.”

“I describe it as your muscles dying – basically it weakens your body, you lose all your muscles over time.”
 
Larisa

Myositis Patient

She turned to her doctor for answers, insisting something was wrong. Yet blood work, CTs, and MRIs all came back inconclusive. It wasn’t until a creatine kinase (CK) test – which is used to check for damage to muscles, heart or brain tissue – returned an abnormally high result that everything changed. She was told to go to the emergency room immediately with a warning that her organs could be shutting down. Larisa was diagnosed with immune-mediated necrotizing myopathy, or IMNM, one of the most severe subtypes of autoimmune myositis.

Autoimmune myositis, which encompasses several subtypes, including IMNM and dermatomyositis (DM),1 is a serious, life-altering disease in which the body’s own immune system attacks itself, potentially causing irreversible muscle loss and damage to the lungs, heart, skin and other organs, if left untreated. This can severely impact patients’ independence and their overall quality of life.1,2,3

Patients living with autoimmune myositis frequently experience significant pain and fatigue. In one survey, more than 90% of patients reported suffering from either current or past pain. Another study looking at fatigue showed that around two-thirds of patients experience moderate-to-severe fatigue.4,5.

The impact on patients’ lives can be far-reaching, with 45% of patients in a recent observational study reporting overall work impairment, and in a separate study, 76% of caregivers shared they face at least mild to moderate caregiver burden as a result of looking after someone with autoimmune myositis.6,7.

91%

of patients

suffer from either current or past pain.4

2/3

of patients

experience moderate-to-severe fatigue.5

45%

of patients

reported overall work impairment.6

76%

of caregivers

face at least mild to moderate caregiver burden as a result of looking after someone with autoimmune myositis.7

“In autoimmune diseases such as autoimmune myositis, the immune system starts to create ‘bad’ antibodies – autoantibodies that target the body’s own tissues. We are learning more and more how significant these autoantibodies are in terms of driving disease progression,” Leentje De Ceuninck, PhD, Principal Clinical Scientist at argenx, explains.

Leentje De Ceuninck
“We are learning more and more how significant autoantibodies are in terms of driving disease progression.”
Leentje De Ceuninck, PhD

Principal Clinical Scientist, argenx

“IMNM often causes a rapid decline in muscle strength. Delayed treatment can lead to permanent muscle damage, where muscle is replaced by fat and muscle strength may not fully recover. DM involves both muscle weakness and distinctive, often painful or highly visible skin rashes. This variability makes myositis genuinely hard to recognize, diagnose, and treat,” De Ceuninck says.8

The diagnostic odyssey can be further compounded by patients having to navigate a disjointed healthcare system to receive a diagnosis, and once patients are diagnosed, physicians have a limited set of treatment options at their disposal.2

Time is Muscle

“We know that there is a limited window to act before damage is done,” says De Ceuninck.

For IMNM patients like Larisa, there is an urgent need to treat patients before fat replaces healthy muscle.9

“I describe it as your muscles dying – basically it weakens your body, you lose all your muscles over time. In my case, it was slow at first, and then it was rapid,” Larisa explains.

Even after starting treatment, Larisa was unable to walk up and down stairs and needed help with simple tasks, like washing her hair and showering.

“The first year was probably the most difficult. Adjusting everything in my life, slowing way down, walking with a cane,” says Larisa, who has described autoimmune myositis as an illness that stole her dreams for the future.

There are no approved therapies for IMNM, and only one for DM, leaving clinicians to rely on broad immunosuppressants and corticosteroids that do not address the underlying mechanisms driving the disease10,11 – up to 80% of patients report long-term disability despite receiving some form of treatment.12

For Larisa, that reality has meant years of infusions and steroids – a demanding medication regimen with side effects that have reshaped her body and mind. For clinicians, alleviating the disease burden without inducing a treatment burden is an ongoing struggle.

Up to

80%

of treated patients still face permanent, life-altering physical limitations.12

A Community That Deserves More

Beyond the physical impact, autoimmune myositis can cause fear, social isolation, and a general sense of invisibility.13 The impact on families can be equally profound as their plans and hopes for the future can also be upended by this condition.9

Through continued research into the immune mechanisms that drive autoimmune myositis, argenx is committed to finding new treatment solutions that address the underlying drivers of the disease.

“It has been a really, really long road. It's been tough,” Larisa says. “My life has changed a lot, but I need to fight for myself. I hope that other people who have my condition know that there’s a community out there. It’s okay to cry. It’s okay to be upfront with your doctor to say that you need more information, and to ask for it.”

For more community-driven resources for people living with myositis, please go to myositiscollab.com.

References:

  1. Lundberg IE, et al. Nat Rev Dis Primers. 2021;7(1):86
  2. Oldroyd A, et al. Clin Med (Lond). 2017;17(4):322–328
  3. Oldroyd, et al. BMC Rheumatol. 2020;4:47
  4. Bhashyam A, et al. Rheumatology (Oxford). 2022;62(1):264-269.
  5. George TB, et al. Semin Arthritis Rheum. 2025;73:152730.
  6. Peng Z, et al. Rheumatology (Oxford). 2024;63:1113-1122.
  7. Brady P, et al. Qual Life Res. 2025;34(7):1913-1924.
  8. Martins EF, et al. Int J Mol Sci. 2025;26(7):3302
  9. Pinal-Fernandez I, et al. Curr Rheumatol Rep. 2018;20:21
  10. Suh J, Amato AA. Muscle Nerve. 2024 Aug;70(2):166-172.
  11. Neves A, et al. Rheumatology, 2024, 63, 2938–2947
  12. Marie I. Curr Rheumatol Rep. 2012 Jun;14(3):275-85.
  13. Paula Eichenbrenner, et al. The Myositis Association. Mental Health Coping Strategies Practiced by People Living with Myositis: Results of a Qualitative Survey. https://www.myositis.org/wp-content/uploads/2026/06/Mental-Health-Poster-for-GCOM-2026.pdf

 

US-NON-26-00269

Find Support and Resources

For more community-driven resources for people living with myositis, visit The Myositis Collab.

Loading...

Loading...

It's taking longer than expected...